← Leaderboards
Joan M Bull
University Of Texas Hlth Sci Ctr Houston
$523,420
Attributed
$523,420
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$523,420 · 5
By mechanism
R01$500,045 · 1
M01$23,375 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Vittorio Cristini$4,662,941
- Kathleen A Kennedy$2,877,534
- Jon E. Tyson$8,331,717
- Charles S Cox$8,111,868
- Xianglin Du$6,062,197
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyDoxorubicinClinical ResearchHuman SubjectCombination Cancer TherapyHuman Therapy EvaluationNeoplasm /Cancer ThermotherapyMetastasisCytotoxicityFluorouracilCombination ChemotherapyBreast NeoplasmsDna RepairDna DamageBody TemperatureInterferon AlphaLaboratory RatAntineoplasticsHyperthermiaDrug ResistanceDrug Administration Rate /DurationClinical Trial Phase IiCombination TherapyDosage Forms
Grant awards (12)
TRIAL OF CISPLATIN AMP;GEMCITABINE HCL COMBINED WITH WHOLE BODY HYPERTHERMIA$7,568
M01 · FY2005 · RR
DRUGS + HYPERTHERMIA IN PANCREATIC CANCER$7,026
M01 · FY2005 · RR
WHOLE BODY HYPERTHERMIA WITH DOXIL/5FU IN PATIENTS WITH ADVANCED MALIGNANCY$2,161
M01 · FY2005 · RR
Trial of cisplatin &gemcitabine HCl w/ hyperthermia$4,965
M01 · FY2004 · RR
Whole body hyperthermia with Doxil/5FU in patients$993
M01 · FY2004 · RR
Drugs + hyperthermia in pancreatic cancer$662
M01 · FY2004 · RR
OPTIMIZING CANCER CHEMOTHERAPY$66,321
R01 · FY2002 · CA
Phase II trial of hypothermia with 5-fluorouracil/doxorubicin in malignancy$0
M01 · FY2002 · RR
OPTIMIZING CANCER CHEMOTHERAPY$220,067
R01 · FY2001 · CA
Phase II trial of hypothermia with 5-fluorouracil/doxorubicin in malignancy$0
M01 · FY2001 · RR
OPTIMIZING CANCER CHEMOTHERAPY$213,657
R01 · FY2000 · CA
Phase II trial of hypothermia with 5-fluorouracil/doxorubicin in malignancy$0
M01 · FY2000 · RR